Browse the evidence

Metabolic bariatric surgery (MBS) procedures, specifically Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), single anastomosis duodenal-ileal bypass (SADI), and biliopancreatic diversion (BPD), provide superior long-term total body weight loss (TBWL) compared to obesity management medications (OMM) and endoscopic bariatric procedures (EBP).

If you are struggling with obesity and lifestyle changes alone have not provided sufficient long-term results, metabolic bariatric surgery (specifically RYGB, SG, SADI, or BPD) offers the highest probability of significant, sustained weight loss. While newer medications (semaglutide, tirzepatide) are excellent short-to-medium term options and comparable to surgery initially, surgery tends to maintain higher efficacy over the long term (3+ years). Consult a specialist to determine if you are a candidate for these procedures, especially if your BMI is >= 40 kg/m2.

Combined exercise and pharmacotherapy significantly reduces systolic and diastolic blood pressure and triglycerides compared to exercise alone, but does not significantly improve fasting glucose, HDL, or LDL.

While adding medication to exercise improves blood pressure and triglycerides, it may not significantly improve fasting glucose or cholesterol levels (HDL/LDL) compared to medication alone. Focus on the weight loss and blood pressure benefits.

The EMP16 combination therapy significantly improves the Fatty Liver Index (FLI) and reduces visceral adiposity index (VAI) more effectively than conventional orlistat, suggesting specific benefits for liver health beyond general weight loss.

If you have fatty liver or high visceral fat, this specific combination pill (EMP16) may offer better liver health improvements than standard orlistat. It significantly reduces the Fatty Liver Index compared to conventional treatments.

The quality and source of macronutrients (e.g., plant-based proteins, unsaturated fats) are more important for long-term health outcomes than the specific macronutrient ratio (low-carb vs. low-fat).

Don't just count macros; focus on the quality of your food. Replace refined carbohydrates and saturated fats with whole grains, vegetables, nuts, and unsaturated fats. This improves long-term health more than just restricting calories.

High sodium intake is the leading dietary risk factor for mortality globally, responsible for 3 million deaths annually.

High sodium intake is a major driver of early death globally. To protect your health, aim to reduce your sodium intake to the optimal range of 1-3 grams per day, as excessive consumption significantly increases your risk of cardiovascular disease and mortality.

Low intake of whole grains is the leading dietary risk factor for disability-adjusted life years (DALYs) globally, responsible for 3 million deaths.

Not eating enough whole grains is a major contributor to early death and disability. To improve your health, increase your intake of whole grains to the optimal range of 125g per day, as this is a leading factor in preventing chronic disease.

Low intake of fruits is the third leading dietary risk factor for mortality globally, responsible for 2 million deaths.

Not eating enough fruit is a major contributor to early death. To protect your health, increase your fruit intake to the optimal range of 250g per day, as this is a leading factor in preventing chronic disease.

GLP-1-based therapies (semaglutide, tirzepatide) cause lean mass loss proportional to total weight loss (approx. 15-45%), but this reduction is adaptive and accompanied by improved muscle quality (reduced fat infiltration), resulting in preserved or improved muscle function and strength.

If you are taking a GLP-1 medication like semaglutide or tirzepatide, expect to lose some muscle along with fat. This is normal and proportional to your weight loss. Crucially, these drugs often improve muscle quality by reducing fat inside the muscle, which helps preserve your strength and function. To maximize muscle retention, ensure you are consuming adequate protein and engaging in resistance training if possible.

Reducing saturated fat intake reduces the risk of combined cardiovascular events, primarily driven by a reduction in coronary heart disease events, with no significant effect on all-cause or cardiovascular mortality.

To lower your risk of heart disease events, try reducing your intake of saturated fats (found in red meat, full-fat dairy, butter, etc.). This change is associated with fewer heart attacks and other cardiovascular events. However, don't expect this change alone to significantly extend your lifespan or prevent all heart-related deaths. Focus on a balanced diet rather than just cutting one nutrient.

SGLT2 inhibitors reduce blood pressure and body weight in patients with Type 2 Diabetes.

SGLT2 inhibitors can help you lose a small amount of weight (about 1.7 kg or 2.4%) and lower your blood pressure. This is achieved through osmotic diuresis and reduced body fat mass. These effects contribute to overall cardiovascular and renal health.

GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) induce significant weight loss and provide renoprotective effects (reduced albuminuria and slower eGFR decline) in adults with chronic kidney disease (CKD), with efficacy potentially maintained or enhanced in lower eGFR subgroups.

If you have CKD and obesity, newer GLP-1 medications (like semaglutide or tirzepatide) are highly effective for weight loss and may actually protect your kidneys by reducing protein in urine and slowing kidney function decline. Unlike diet and exercise alone, which often fail long-term, these drugs target the hormonal drivers of obesity. Start with a low dose and increase slowly to avoid stomach issues, and stay hydrated to protect your kidneys.

Meal timing, specifically higher-calorie breakfasts and overnight fasting, helps prevent obesity.

Eat a larger breakfast and finish eating earlier in the evening. This aligns with your body's natural clock and may help prevent obesity. Avoid skipping breakfast and late-night snacking.

GLP-1 receptor agonists (e.g., liraglutide, semaglutide) resolve MASH histology primarily through substantial weight loss and improved insulin resistance, rather than direct hepatocyte effects.

GLP-1 agonists like semaglutide and liraglutide are effective treatments for MASH, but their primary benefit comes from the weight loss and metabolic improvements they induce, not a direct 'liver cure.' Expect significant weight loss (often 10-15%+), but also manage expectations regarding side effects like nausea, which are common initially. These drugs resolve MASH in a majority of patients but may not reverse advanced fibrosis as effectively. Consult a specialist to determine if the benefits outweigh the burden of injection and side effects for your specific liver stage.

Nationwide substitution of regular discretionary salt with potassium-enriched salt substitutes (20-30% KCl) in China yields a substantial net reduction in cardiovascular disease mortality by lowering systolic blood pressure, even when accounting for the increased risk of hyperkalemia in individuals with chronic kidney disease.

Replace your regular table salt and cooking salt with a potassium-enriched salt substitute (containing 20-30% potassium chloride). Use it in the same amounts you currently use regular salt, but try to use it slightly more sparingly if possible. This change lowers blood pressure and significantly reduces the risk of heart disease and stroke for the general population. If you have advanced kidney disease, consult your doctor, but note that even for kidney patients, the cardiovascular benefits of this switch generally outweigh the risks of potassium toxicity.

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) produce significant real-world weight loss, but effectiveness is substantially lower than in clinical trials due to high discontinuation rates (20-50%) and suboptimal dosing in routine care.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, but their real-world success depends entirely on sticking with them. Many people stop early due to side effects or cost, leading to less weight loss than seen in trials. To get the best results, you must manage side effects (which often fade) and ensure you can afford the medication long-term. If you adhere to the full dose and stay on the drug, your weight loss can match what is seen in clinical trials.

Combining moderate-to-vigorous exercise with GLP-1 receptor agonist (liraglutide) treatment preserves hip and lumbar spine bone mineral density (BMD) during significant weight loss, whereas GLP-1 RA treatment alone reduces BMD at these sites despite similar weight loss.

If you are using a GLP-1 medication like liraglutide or semaglutide for weight loss, you must incorporate regular exercise to protect your bones. This study shows that while the medication alone might reduce bone density at the hip and spine, adding moderate-to-vigorous exercise (like cycling and circuit training) completely preserves bone density, even when you lose a significant amount of weight. Do not rely on the medication alone for skeletal health.

Personalized Type 2 Diabetes management, which tailors pharmacotherapy to individual phenotypic, clinical, and personal factors, improves medication adherence, patient satisfaction, and health outcomes compared to rigid algorithmic approaches.

Work with your doctor to build a treatment plan that fits your specific health profile (like kidney or heart status) and your personal life (like fear of hypoglycemia or preference for pills vs. injections). This collaborative approach leads to better adherence and fewer complications than following a generic, one-size-fits-all checklist.

Personalized glycemic targets should be less aggressive in older patients or those with reduced life expectancy to minimize hypoglycemia risk and polypharmacy burden.

If you are older or have other serious health conditions, your doctor may aim for a higher blood sugar target to keep you safe from dangerous lows and side effects. This focuses on your quality of life rather than just a number.

Short-term high-volume resistance training induces muscle hypertrophy primarily through sarcoplasmic expansion (increased sarcoplasmic proteins and glycolytic enzymes) rather than myofibrillar accretion, often accompanied by a decrease in actin and myosin concentrations.

If you are new to resistance training or returning after a break, your initial muscle size gains may come largely from increased fluid and metabolic enzymes (sarcoplasm) rather than thicker muscle fibers. This means you might see visual size increases before significant strength gains. This is a normal, healthy adaptation to high-volume training and does not negate the value of the training.

Short-term step reduction (<1000 steps/day) in older adults triggers rapid metabolic perturbations indicating muscle energy decline and protein degradation, which are not fully reversible after two weeks of resumed normal activity.

If you are an older adult, even a short break from your normal walking routine (less than 1,000 steps a day) can trigger metabolic changes in your muscles that suggest protein breakdown. These changes don't always bounce back quickly when you start moving normally again. To protect your muscle health, try to maintain a baseline level of daily movement rather than taking long breaks, especially if you are already at risk for metabolic issues.

Replacing saturated fatty acids (SFA) with polyunsaturated fatty acids (PUFA) reduces cardiovascular disease (CVD) risk, whereas replacing SFA with refined carbohydrates (starches and sugars) has a neutral or adverse effect on CVD risk.

Don't just cut fat; look at what you replace it with. If you cut saturated fat (like butter or fatty meat) but replace it with refined carbs (white bread, sugar), your heart risk may not improve or could get worse. Instead, replace saturated fats with unsaturated fats (like olive oil, nuts, or fish). This substitution, not just calorie cutting, is what lowers cardiovascular disease risk.

Sugar-sweetened beverages (SSB) promote cardiometabolic disease and obesity through mechanisms beyond simple caloric excess, including specific metabolic effects of fructose and promotion of de novo lipogenesis.

Avoid sugar-sweetened beverages. They are linked to higher risks of type 2 diabetes and heart disease through specific metabolic pathways (like liver fat production) that go beyond just adding calories. Water, unsweetened tea, or coffee are better choices.

Weight loss achieved via a very-low-carbohydrate, high-saturated-fat diet does not impair endothelial function (measured by flow-mediated dilatation) and improves other cardiovascular risk markers, refuting the hypothesis that such diets inherently damage vascular health.

If you are overweight and have abdominal obesity, losing weight through a very-low-carbohydrate, high-saturated-fat diet does not appear to harm your blood vessel health (endothelial function) over an 8-week period. In fact, other markers of inflammation and clotting risk improved. The key factor seems to be the weight loss itself, which may counteract the negative effects of high saturated fat intake seen in people who don't lose weight.

A very-low-carbohydrate, high-saturated-fat diet leads to greater weight loss and abdominal fat reduction compared to a high-carbohydrate, low-saturated-fat diet, but results in less favorable changes in LDL cholesterol and C-reactive protein.

A very-low-carbohydrate diet may help you lose slightly more weight and abdominal fat than a high-carbohydrate diet over 8 weeks. However, this comes at the cost of less improvement in LDL cholesterol and inflammation (CRP) compared to a high-carbohydrate diet. If you have high cholesterol or inflammation, a high-carbohydrate diet might be a better choice for your cardiovascular markers, even if weight loss is slightly slower.